Education
About Us
Working with TipRanks
Follow Us
Aurora Cannabis (ACB)
NASDAQ:ACB
ACB Stock Chart & Stats
$3.48
-$0.24(-5.15%)
At close: 4:00 PM EST
$3.48
-$0.24(-5.15%)
Day’s Range― - ―
52-Week Range$3.28 - $6.91
Previous Close$4.5
Volume634.82K
Average Volume (3M)1.18M
Market Cap
$197.64M
Enterprise Value$314.42M
Total Cash (Recent Filing)$154.44M
Total Debt (Recent Filing)$134.19M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Jun 18, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding56,703,785
10 Day Avg. Volume1,443,744
30 Day Avg. Volume1,178,596
Financial Highlights & Ratios
PEG Ratio-2.12
Price to Book (P/B)0.61
Price to Sales (P/S)1.01
P/FCF Ratio-121.14
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue0.85
Enterprise Value/Gross Profit3.02
Enterprise Value/Ebitda13.38
Forecast
1Y Price Target
$6.70Price Target Upside92.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's balance sheet offers optionality even in tough conditions.
Market PotentialA federal re-scheduling in the U.S. should provide benefits including increased research, lower stigma, improve access to capital, and unlock the world's biggest addressable cannabis market.
Strategic ShiftACB has turned over a proverbial new leaf following the reset in the cannabis industry, now with a focus on responsible growth.
Bears Say
Industry RisksThere are lingering risks in the emerging cannabis industry including rampant illicit markets, limited insurance coverage, and unpredictable path to further de-regulation.
Operational ChallengesThere are administration delays in settlement payments.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis’s price range in the past 12 months?
Aurora Cannabis lowest stock price was $3.28 and its highest was $6.91 in the past 12 months.
What is Aurora Cannabis’s market cap?
Aurora Cannabis’s market cap is $197.64M.
When is Aurora Cannabis’s upcoming earnings report date?
Aurora Cannabis’s upcoming earnings report date is Jun 18, 2026 which is in 130 days.
How were Aurora Cannabis’s earnings last quarter?
Aurora Cannabis released its earnings results on Feb 04, 2026. The company reported $0.022 earnings per share for the quarter, missing the consensus estimate of $0.098 by -$0.076.
Is Aurora Cannabis overvalued?
According to Wall Street analysts Aurora Cannabis’s price is currently Undervalued.
Does Aurora Cannabis pay dividends?
Aurora Cannabis does not currently pay dividends.
What is Aurora Cannabis’s EPS estimate?
Aurora Cannabis’s EPS estimate is -0.04.
How many shares outstanding does Aurora Cannabis have?
Aurora Cannabis has 56,703,785 shares outstanding.
What happened to Aurora Cannabis’s price movement after its last earnings report?
Aurora Cannabis reported an EPS of $0.022 in its last earnings report, missing expectations of $0.098. Following the earnings report the stock price went down -7.635%.
Which hedge fund is a major shareholder of Aurora Cannabis?
Currently, no hedge funds are holding shares in ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.70 (92.53% Upside)
$6.70 (92.53% Upside)
Blogger Sentiment
Bullish
ACB Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
News Sentiment
Neutral
Bullish news 55%
Bearish news 45%
Bearish news 45%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.32%
12-Months-Change
Fundamentals
Return on Equity
-16.05%
Trailing 12-Months
Asset Growth
-6.13%
Trailing 12-Months
Company Description
Aurora Cannabis
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
ACB Company Deck
ACB Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized material progress: top-line growth driven by a focused medical-cannabis strategy, strong high-single-digit revenue growth, healthy adjusted gross margins (62% consolidated; 69% medical), record international execution (Germany, Poland, Australia), positive adjusted EBITDA and free cash flow, and a conservative balance sheet with $154M cash and no cannabis-related debt. Management also announced strategic moves (exiting select Canadian consumer markets, divesting plant propagation stake, and an ATM up to $100M) designed to reallocate resources to higher-margin global medical markets. Offsetting this are deliberate shrinkage in the lower-margin Canadian consumer business (48% revenue decline by design), significant margin deterioration and write-offs in the plant propagation segment, higher SG&A to support international growth, modest YoY decline in adjusted EBITDA, and lower free cash flow versus the prior year. Overall, the operational and financial positives and the clear strategy to concentrate on a higher-margin global medical opportunity outweigh the operational headwinds and one-time/divestiture-related impacts, indicating constructive momentum and a cautiously positive outlook.View all ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
$6.70
▲(92.53% Upside)
Technical Analysis
Canopy Growth
―
Cronos Group
―
Curaleaf Holdings
―
Green Thumb Industries
―
Trulieve Cannabis
―
Ownership Overview
0.53% Insiders
0.11% Mutual Funds
<0.01% Other Institutional Investors
95.59% Public Companies and
Individual Investors